Research programme: nicotinic acetylcholine receptor agonists - Odan Laboratories

Drug Profile

Research programme: nicotinic acetylcholine receptor agonists - Odan Laboratories

Alternative Names: ASM-002; nAchR agonists - Odan Laboratories

Latest Information Update: 05 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Asmacure
  • Developer Odan Laboratories
  • Class Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic asthma

Most Recent Events

  • 05 Jan 2016 This programme is still in active development
  • 19 Aug 2015 Odan Laboratories acquires Asmacure Ltee
  • 25 May 2006 Preclinical trials in Allergic asthma in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top